#biotech

#biotech

Relay Therapeutics is a clinical-stage precision drug company using its Dynamo platform to design protein-motion-based oncology drugs, led by PI3Kα inhibitor zovegalisib. Shares are up 50.35% year to date and 286.63% over the past year, with a balance sheet showing $554.52 million in cash and investments, supporting runway into 2029. The bull case includes 12 buy ratings and an FDA Breakthrough Therapy designation for zovegalisib.

Regeneron Pharmaceuticals has reported a temporary interruption of bulk manufacturing production at its Raheen facility in Co Limerick due to unanticipated facility repairs.

The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names.

At Koodos, we're building something fundamentally different. Our focus is on backing companies that genuinely improve people's lives, while helping investors access opportunities they wouldn't normally see.

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, confirming its commitment to advancing healthcare and life sciences.

The JP Morgan Healthcare Conference is back in town, and while biotech executives are 80% men, a renegade group of women executives took over Union Square in so many pink pantsuits it would have made Mary Tyler Moore proud. If you haven't noticed, the JP Morgan Annual Healthcare Conference is in town again, and the famed big-money biotech conference runs through Thursday. It's considered SF's second largest revenue-generating conference of the year, behind only Dreamforce.

The U.S. stock market is drifting near its record levels on Wednesday following mixed reactions to profit reports from Macy's, Marvell Technologies, and other companies. The S&P 500 rose 0.2% and pulled within 0.7% of its all-time high set in late October. The Dow Jones Industrial Average was up 174 points, or 0.6%, as of 11:50 a.m. Eastern time, and the Nasdaq composite was virtually unchanged.

Teleskope - $25M Series A Teleskope, a data protection and security platform, has raised $25M in Series A funding led by M13. Founded by Elizabeth Nammour and Julie Trias in 2022, Teleskope has now raised a total of $32.2M in reported equity funding. AUI - $20M Venture AUI, the company building neuro-symbolic foundation models for task-oriented conversational AI, has raised $20M in Venture funding from New Era Capital Partners and eGateway Capital.

We're all living in a cyberpunk novel now. Unconstrained billionaires have space programs and robot armies. People are falling in love with and marrying AI chatbots. You can make movies where you're the star by typing a few sentences. Companies offer designer babies as a service. We've got brain implants for controlling computers, flying cars, robotic surgery, AI-controlled prosthetic limbs, and millions of drones in the sky. So why is the most effective form of communication still a hand-written note?

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood ( NASDAQ:HOOD ) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday people to build portfolios without needing thousands upfront. But that doesn't mean buying cheap stocks is always a good idea, since a low price could signal company problems - and certainly steer clear of penny stocks, which carry high risks of fraud and volatility. Sometimes, though, a low share price signals real opportunity.

Despite my husband and my family's belief that our decision to leave the matrix to live on a homestead in the mountains was spontaneous, people don't just wake up one day and realize they don't fit in. That moment of clarity is the culmination of years of being different. After all, in high school, I was voted least likely to conform.

Gameto, a biotech company focused on women's reproductive health using cell engineering, has raised $44M in Series C funding led by Overwater Ventures.

Concentra Biosciences is rapidly acquiring struggling biotech companies, taking advantage of Bay Area firms' difficulties, including its recent purchase of Cargo Therapeutics, which faced severe setbacks this year.

The market for these instruments has clearly evaporated due to government funding cuts, pushing Eikon to pause the development of advanced lab tools for researchers.

Elizabeth Holmes, despite serving a prison sentence for fraud, is supporting her partner's new medical startup, Haemanthus, which echoes the technology of Theranos.

Glycomine's progress towards delivering the first disease-modifying therapy for a rare genetic disorder was bolstered by a $115 million Series C funding round.